Patents Examined by Danah Al-Awadi
  • Patent number: 9510928
    Abstract: The present invention relates to a composite implant comprising: a prosthetic fabric having a first side and a second side, a non-porous film of bacterial cellulose secured to the first side of the fabric. The invention further relates to a method of making such an implant.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: December 6, 2016
    Assignee: Sofradim Production
    Inventors: Yves Bayon, Sébastien Ladet, Olivier Lefranc, Philippe Gravagna
  • Patent number: 9504658
    Abstract: A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: November 29, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Dave A. Miller, Jason T. McConville, James W. McGinity, Robert O. Williams, III
  • Patent number: 9504641
    Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 29, 2016
    Inventor: Richard C. K. Yen
  • Patent number: 9497973
    Abstract: Elasmobranch-repelling compositions are prepared from elasmobranch carcasses. Extraction of these elasmobranch carcasses with polar solvent after a period of aerobic decay yields semiochemical repellents that induce a flight reaction in sharks when introduced into the sharks' oceanic proximity.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: November 22, 2016
    Inventors: Eric Matthew Stroud, Jean Marie Pachucki, Michael Matthew Herrmann
  • Patent number: 9486410
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: November 8, 2016
    Assignee: Bend Research, Inc.
    Inventors: Michael E. Perlman, Ravi M. Shanker, Walter C. Babcock, Dwayne Thomas Friesen, Mark D. Rabenstein, Dan Tod Smithey
  • Patent number: 9474722
    Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: October 25, 2016
    Assignee: NOVEN PHARMACEUTICALS, INC.
    Inventor: Robert L. Lambert
  • Patent number: 9468627
    Abstract: The present invention concerns the treatment of serotonergic dysregulation disorders and/or augmentation of serotonin levels in the brain by add-on treatments to serotonin enhancers, and slow-release formulations of 5-hydroxytryptophan (5-HTP) therefor.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: October 18, 2016
    Assignee: Duke University
    Inventors: Jacob P. R. Jacobsen, Marc G. Caron
  • Patent number: 9468682
    Abstract: According to this invention, compositions and methods for increasing the extent of penetration of a biologically active substance into the tissues and organs are proposed, the methods comprising administration of the biologically active substance in combination with one or more chaotropic agents, e.g., ammonium sulfate.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: October 18, 2016
    Assignee: Joint-stock company “High Tech”
    Inventor: Olga Klimova
  • Patent number: 9463206
    Abstract: Described herein are tissue grafts produced by contacting dehydrated placental tissue grafts with a cross-linking agent. The tissue grafts described herein provide barrier and prevent the migration of a bioactive agent from the wound. Thus, the tissue grafts enhance wound healing while preventing the undesirable migration of a bioactive agent from the wound. Methods for making and using the cross-linked grafts are also described herein.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 11, 2016
    Assignee: MiMedx Group, Inc.
    Inventors: Tom Koob, John Daniel, Randall Spencer
  • Patent number: 9456993
    Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 4, 2016
    Assignee: NOVEN PHARMACEUTICALS, INC.
    Inventor: Robert L. Lambert
  • Patent number: 9453848
    Abstract: The present invention relates to the use of a complex form of calmodulin-like skin protein (CLSP), of polypeptides derived from this protein or of analogues thereof, as a marker for evaluating a state of an epithelium. The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: September 27, 2016
    Assignee: L'OREAL
    Inventors: Mark Donovan, Dominique Bernard
  • Patent number: 9452406
    Abstract: Disclosed are methods of preparing stable gas-in-water dispersions by silicic acid complexation of micron-sized gas bubbles, and stable dispersions prepared by silicic acid complexation. Compositions and products comprising the dispersions are also disclosed. Dispersions may be stable over an extended period of time at room temperature.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 27, 2016
    Assignee: L'OREAL
    Inventors: Vance Bergeron, Jean-Thierry Simonnet, Florence Levy, Aurelie Lafuma, Stephane Santucci
  • Patent number: 9445998
    Abstract: A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 20, 2016
    Assignee: Bend Research, Inc.
    Inventors: Leah E. Appel, Walter C. Babcock, Dwayne T. Friesen, Roderick J. Ray, Daniel T. Smithey, Sheri L. Shamblin, Ravi M. Shanker
  • Patent number: 9386766
    Abstract: An attractant composition suitable for attracting Lepidopterous insects, particularly Helicoverpa armigera, for use as an insect lure in a control method aimed at reducing pest damage to crops. The preferred attractant composition comprises phenylacetaldehyde, salicylaldehyde and at least one compound selected from the group comprising: methyl-2-methoxybenzoate, linalool and limonene.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: July 12, 2016
    Assignee: University of Greenwich
    Inventor: Alan Cork
  • Patent number: 9370470
    Abstract: Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: June 21, 2016
    Assignee: SUNEVA MEDICAL, INC.
    Inventor: Louis Masi
  • Patent number: 9370469
    Abstract: Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 21, 2016
    Assignee: SUNEVA MEDICAL, INC
    Inventor: Louis Masi
  • Patent number: 9370603
    Abstract: Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 21, 2016
    Assignee: SUNEVA MEDICAL, INC.
    Inventor: Louis Masi
  • Patent number: 9365489
    Abstract: The present invention relates to a method for reducing the production of methane emanating from the digestive activities of a ruminant and or for improving ruminant animal performance by using, as active compound at least one nitrooxy alkanoic acid and/or derivative thereof, which is administrated to the animal together with the feed. The invention also relates to the use of these compounds in feed and feed additives such as premix, concentrates and total mixed ration (TMR) or in the form of a bolus.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: June 14, 2016
    Assignee: DSM IP ASSETS B.V.
    Inventors: Stephane Duval, Maik Kindermann
  • Patent number: 9364432
    Abstract: The described invention provides a flowable sustained release microparticulate composition, a kit for treating at least one cerebral artery in a subarachnoid space at risk of interruption due to a brain injury, a method of preparing the composition, and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: June 14, 2016
    Assignee: Edge Therapeutics, Inc.
    Inventors: R. Loch Macdonald, Brian A. Leuthner
  • Patent number: 9345665
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 24, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer